AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27663941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG) 1 g/kg/day on 2 consecutive days
Number of subjects: 35
Study 27663941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27663941 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label IVIG (for nonresponders)
Number of subjects: 35
Study 24469371 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional apicoectomy (group 1)
Number of subjects: 843
Study 24469371 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern microsurgical apicoectomy using burns for osteotomy (group 2)
Number of subjects: 843
Study 24469371 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern microsurgical apicoectomy using piezo-osteotomy (group 3)
Number of subjects: 843
Study 24469371 — intervention group
Group type: COMPARATOR
Intervention: Silver amalgam root-end filling material
Number of subjects: 843
Study 24469371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate root-end filling material
Number of subjects: 843
Study 22699884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 65
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariva
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Marlboro Snus
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Commit nicotine lozenge (2 mg)
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: own brand cigarettes
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: Quest cigarettes
Number of subjects: 28
Study 19346218 — intervention group
Group type: EXPERIMENTAL
Intervention: sham smoking (unlit cigarette)
Number of subjects: 28
Study 18035135 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 10
Study 18035135 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) followed by left lateral position (LLP)
Number of subjects: 10
Study 18035135 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP) first
Number of subjects: 10
Study 16109319 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4937
Study 16109319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study 11965579 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 1 x 10(6) U/d (Group A)
Number of subjects: 15
Study 11965579 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 3 x 10(6) U three times weekly (Group B)
Number of subjects: 15
Study 11965579 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 1 x 10(6) U/d, plus ribavirin, 400 mg twice daily (Group C)
Number of subjects: 15
Study 11965579 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study 10099140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy (dose sufficient to decrease baseline heart rate by 25%)
Number of subjects: 89
Study 10099140 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (performed weekly until varices were obliterated)
Number of subjects: 89
Study 7739944 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 21
Study 7739944 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 21
Study 1675042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 micrograms.kg‐1
Number of subjects: 96
Study 1675042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 micrograms.kg‐1
Number of subjects: 96
Study 1675042 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 96
Study 1675042 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2.0 micrograms.kg‐1
Number of subjects: 96
Study 399787 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeticon
Number of subjects: 0
Study 399787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 81
Study 31363328 — intervention group
Group type: COMPARATOR
Intervention: No stress ulcer prophylaxis (control group)
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risk factors (APACHE II >18, age >65, mechanical ventilation, sedation)
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stay >10 days
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease as underlying disorder
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation and previous antibiotic therapy
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher values of gastric content pH
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization with Acinetobacter spp.
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors that accelerated occurrence of HAP
Number of subjects: 81
Study 31363328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 81
Study 27297097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological surveillance
Number of subjects: 3399
Study 27297097 — intervention group
Group type: COMPARATOR
Intervention: Initial colposcopy
Number of subjects: 3399
Study 25139063 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sustained muscular pain challenge
Number of subjects: 34
Study 23562192 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Levocetirizine
Number of subjects: 40
Study 23562192 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Desloratadine
Number of subjects: 40
Study 23562192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21276671 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Cannula (NC) group, weaned off NCPAP when FiO(2) was ≤0.30 to NC (2 L/min)
Number of subjects: 60
Study 21276671 — intervention group
Group type: COMPARATOR
Intervention: No-NC group, kept on NCPAP until FiO(2)=0.21 for 24 h, then weaned off NCPAP
Number of subjects: 60
Study 19351943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), n = 70
Number of subjects: 134
Study 19351943 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC), n = 64
Number of subjects: 134
Study 16411996 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwi Omnicup
Number of subjects: 404
Study 16411996 — intervention group
Group type: COMPARATOR
Intervention: Conventional vacuum cups
Number of subjects: 404
Study 15319494 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 3224
Study 15319494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3224
Study 11747915 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Number of subjects: 306
Study 11747915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose of RTS,S/AS02
Number of subjects: 306
Study 11747915 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 306
Study 9406807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied directly onto the skin or onto a piece of quartz fixed to the skin before UV exposure
Number of subjects: 0
Study 9406807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sunscreen applied)
Number of subjects: 0
Study 9406807 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier study with the same sunscreen
Number of subjects: 0
Study 8376638 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based primary prevention psychological program (cognitive-behavioral modification principles)
Number of subjects: 237
Study 8376638 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 237
Study 3777838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalational sedation
Number of subjects: 30
Study 3777838 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia alone
Number of subjects: 30
Study 31597320 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic Faecal Microbiota Transfer (FMT)
Number of subjects: 17
Study 31597320 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Faecal Microbiota Transfer (FMT)
Number of subjects: 17
Study 29976533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GABA group)
Number of subjects: 60
Study 29976533 — intervention group
Group type: COMPARATOR
Intervention: Dexchlorpheniramine (DEX group)
Number of subjects: 60
Study 25406227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation (4 mEq/kg/d)
Number of subjects: 53
Study 25406227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium supplementation
Number of subjects: 53
Study 25406227 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 53
Study 24597683 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated online psychosocial assessment and cognitive behavior therapy (CBT)
Number of subjects: 816
Study 24597683 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care (no formal screening or specialized care)
Number of subjects: 816
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR-MPH)
Number of subjects: 26
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotically controlled-release oral delivery system methylphenidate (OROS-MPH)
Number of subjects: 26
Study 22314126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-MPH to IR-MPH
Number of subjects: 26
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: IR-MPH to OROS-MPH
Number of subjects: 26
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH to IR-MPH
Number of subjects: 26
Study 22314126 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-MPH to OROS-MPH
Number of subjects: 26
Study 20195162 — intervention group
Group type: EXPERIMENTAL
Intervention: SQT-8 (8 days)
Number of subjects: 270
Study 20195162 — intervention group
Group type: EXPERIMENTAL
Intervention: SQT-10 (10 days)
Number of subjects: 270
Study 20195162 — intervention group
Group type: COMPARATOR
Intervention: STT (7 days)
Number of subjects: 270
Study 19000095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (Rtx) treatment
Number of subjects: 0
Study 15894697 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional incentive ($10 with survey)
Number of subjects: 397
Study 15894697 — intervention group
Group type: COMPARATOR
Intervention: Conditional incentive ($10 upon receipt of completed survey)
Number of subjects: 397
Study 11842038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (LI; 400 kcal at 40% of maximal oxygen consumption)
Number of subjects: 16
Study 11842038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HI; 400 kcal at 70% of maximal oxygen consumption)
Number of subjects: 16
Study 11842038 — intervention group
Group type: COMPARATOR
Intervention: Sedentary day (Con)
Number of subjects: 16
Study 11842038 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of men and women
Number of subjects: 16
Study 10510144 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐758 298 (0.25 mg, 1 mg, 5 mg)
Number of subjects: 16
Study 10510144 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐758 298 (1.43 mg)
Number of subjects: 16
Study 10510144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8526962 — intervention group
Group type: COMPARATOR
Intervention: High fresh gas flow rate (6.0 L/min)
Number of subjects: 24
Study 8526962 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal fresh gas flow rate (0.6 L/min)
Number of subjects: 24
Study 1873687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim
Number of subjects: 0
Study 6790048 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol (40 mg)
Number of subjects: 31
Study 6790048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive speech therapy using slowed-speech and relaxation technique
Number of subjects: 31
Study 6790048 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance speech therapy
Number of subjects: 31
Study 29564507 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg for <65 years, 300 mg for >65 years)
Number of subjects: 47
Study 29564507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 27120194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 50
Study 27120194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing TKA
Number of subjects: 50
Study 27120194 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 26084792 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day
Number of subjects: 146
Study 26084792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day
Number of subjects: 146
Study 25060414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 1998
Study 25060414 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (placebo arm)
Number of subjects: 1998
Study 22194326 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 18
Study 22194326 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 18
Study 19542796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant alone
Number of subjects: 57
Study 19542796 — intervention group
Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 57
Study 17286630 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A reconstituted in lidocaine
Number of subjects: 29
Study 17286630 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A reconstituted in normal saline
Number of subjects: 29
Study 15631562 — intervention group
Group type: EXPERIMENTAL
Intervention: lay health advisor (promotora) plus tailored print materials
Number of subjects: 357
Study 15631562 — intervention group
Group type: EXPERIMENTAL
Intervention: tailored print materials only (tailored)
Number of subjects: 357
Study 15631562 — intervention group
Group type: COMPARATOR
Intervention: off-the-shelf print materials (control)
Number of subjects: 357
Study 11840078 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T/NVP/RTV
Number of subjects: 48
Study 11840078 — intervention group
Group type: COMPARATOR
Intervention: d4T/RTV
Number of subjects: 48
Study 11840078 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC/RTV
Number of subjects: 48
Study 14666752 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime
Number of subjects: 109
Study 14666752 — intervention group
Group type: COMPARATOR
Intervention: Local treatment (eosin 5% and alcohol 95%)
Number of subjects: 109
Study 8625054 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (0.5 mg/kg) plus methylprednisolone (125 mg)
Number of subjects: 262
Study 8625054 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg) orally
Number of subjects: 262
Study 8625054 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg) orally plus methylprednisolone (125 mg)
Number of subjects: 262
Study 2285628 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine, 10 mg twice daily
Number of subjects: 10
Study 2285628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7173301 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (8 mg/day)
Number of subjects: 20
Study 7173301 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (1 mg/day)
Number of subjects: 20
Study 31996940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 1 min
Number of subjects: 18
Study 31996940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 5 min
Number of subjects: 18
Study 31996940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg per 70-kg body weight dose of nicotine delivered over 10 min
Number of subjects: 18
Study 31996940 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study 28135841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin for secondary stroke prevention
Number of subjects: 0
Study 26876688 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-QCA
Number of subjects: 90
Study 26876688 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-QCA
Number of subjects: 90
Study 26876688 — intervention group
Group type: COMPARATOR
Intervention: 2D-QCA and 3D-QCA
Number of subjects: 90
Study 23512260 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1 (P1) - customized contrast dose based on time-attenuation response (0.3 ml/kg body weight)
Number of subjects: 60
Study 23512260 — intervention group
Group type: COMPARATOR
Intervention: Protocol 2 (P2) - tailored contrast dose based on body weight (0.7 ml/kg body weight)
Number of subjects: 60
Study 22412028 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) administration
Number of subjects: 22699
Study 20150524 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC 160 µg BID (ex actuator)
Number of subjects: 32
Study 20150524 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC 320 µg BID (ex actuator)
Number of subjects: 32
Study 20150524 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 220 µg BID (ex actuator)
Number of subjects: 32
Study 20150524 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 440 µg BID (ex actuator)
Number of subjects: 32
Study 20150524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18779511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 28
Study 18779511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18779511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateromedial rTMS
Number of subjects: 28
Study 16501030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal-related HRV indexes
Number of subjects: 55
Study 16501030 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR indexes
Number of subjects: 55
Study 16501030 — intervention group
Group type: EXPERIMENTAL
Intervention: FitLT and FitMT
Number of subjects: 55
Study 16501030 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training
Number of subjects: 55
Study 14696789 — intervention group
Group type: EXPERIMENTAL
Intervention: Furoxime (250 mg)
Number of subjects: 12
Study 14696789 — intervention group
Group type: COMPARATOR
Intervention: Zinnat (250 mg)
Number of subjects: 12
Study 14696789 — intervention group
Group type: EXPERIMENTAL
Intervention: Furoxime
Number of subjects: 12
Study 10792119 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (25 mg t.d.s.)
Number of subjects: 30
Study 10792119 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (10 mg t.d.s.)
Number of subjects: 30
Study 8554003 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class II
Number of subjects: 20
Study 8554003 — intervention group
Group type: COMPARATOR
Intervention: NYHA class III
Number of subjects: 20
Study 8554003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency component of the spectrum
Number of subjects: 20
Study 1886589 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH and epinephrine (Group E)
Number of subjects: 20
Study 1886589 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH and dopamine (Group D)
Number of subjects: 20
Study 1886589 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH and catecholamine (both groups)
Number of subjects: 20
Study 7102580 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluoride supplement in divided doses with meals
Number of subjects: 0
Study 7102580 — intervention group
Group type: COMPARATOR
Intervention: Control group with basal diets containing 0.4 mg fluoride per day
Number of subjects: 0
Study 7102580 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluoride supplement
Number of subjects: 0
Study 7102580 — intervention group
Group type: COMPARATOR
Intervention: Control group with basal diets
Number of subjects: 0
Study 30379087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29096678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered alteplase
Number of subjects: 0
Study 26416029 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Collaborative (LC)
Number of subjects: 50
Study 26416029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascading Model (CM)
Number of subjects: 50
Study 26416029 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance Education (DE)
Number of subjects: 50
Study 26416029 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (EBT)
Number of subjects: 50
Study 23415985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication combined with chewing gum
Number of subjects: 30
Study 23415985 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 30
Study 21537935 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy in addition to routine nursing care
Number of subjects: 120
Study 21537935 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study 19303969 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment (3 to 4 injections of insulin daily)
Number of subjects: 19
Study 19303969 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard insulin treatment plus an additional day per week of 3 intravenous pulses over an 8‐hour period
Number of subjects: 19
Study 17347180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80